Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Kyle Mikson CFA
CG

Kyle Mikson CFA

Wall Street Analyst
β˜…β˜…β˜…β˜…β˜…
#184
on 13Foresight Β· ranked by our own returns
65%
Success Rate
+7.2%
Average Return
54 of 83 calls profitable Β· +7.0% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 65% of Kyle Mikson CFA's ratings turned a profit when each position was held for 2 year β€” averaging +7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

124 Buy 56 Hold 0 Sell
Kyle's Stock Coverage 28 ratings Β· 2026-11-17
Company Date Position Consensus β“˜ Price Target β“˜ 2-Yr Return vs S&P 500 β“˜
ILMN
Illumina
Oct 30, 2026 HOLD Buy
-10.0% avg upside
32 analysts
$300.00
27.12% Upside
-14.1% Β·
CDNA
CareDx
Oct 30, 2026 BUY Buy
-41.1% avg upside
18 analysts
$99.00
13.31% Upside
-14.7% Β·
RGEN
Repligen
Oct 28, 2026 HOLD Strong Buy
+1.3% avg upside
25 analysts
$180.00
1.67% Upside
-11.9% Β·
LUCD
Lucid Diagnostics
Oct 23, 2026 BUY Strong Buy
+1104.3% avg upside
8 analysts
$3.00
641.09% Upside
+1.3% Β·
NTRA
Natera
Oct 19, 2026 BUY Strong Buy
-13.3% avg upside
28 analysts
$500.00
20.72% Upside
-28.0% Β·
CAI
Caris Life Sciences, Inc.
Oct 19, 2026 HOLD Strong Buy
-9.5% avg upside
21 analysts
$30.00
12.63% Downside
-35.1% Β·
XGN
Exagen
Oct 19, 2026 BUY Strong Buy
+50.2% avg upside
11 analysts
$11.00
28.06% Upside
-44.4% Β·
TWST
Twist Bioscience
Oct 12, 2026 BUY Strong Buy
-19.2% avg upside
16 analysts
$205.00
34.14% Upside
-26.2% Β·
TEM
Tempus AI, Inc. Class A
Oct 12, 2026 BUY Strong Buy
-0.3% avg upside
25 analysts
$95.00
31.55% Upside
-6.7% Β·
TXG
10x Genomics
Oct 12, 2026 BUY Buy
-7.6% avg upside
19 analysts
$100.00
42.57% Upside
-25.1% Β·
GRAL
GRAIL Inc
Sep 28, 2026 BUY Strong Buy
-18.5% avg upside
9 analysts
$150.00
4.49% Upside
-20.2% Β·
PACB
Pacific Biosciences
Sep 11, 2026 BUY Buy
+73.8% avg upside
14 analysts
β€” +40.0% Β·
BLLN
BillionToOne, Inc. Class A
Sep 02, 2026 BUY Strong Buy
+12.2% avg upside
10 analysts
$120.00
5.82% Upside
+1.4% Β·
QTRX
Quanterix
Aug 17, 2026 HOLD Buy
+548.5% avg upside
8 analysts
$3.00
3.29% Upside
+0.3% Β·
SEER
Seer
Aug 11, 2026 BUY Strong Buy
+561.4% avg upside
5 analysts
$4.00
138.15% Upside
-27.3% Β·
BDSX
Biodesix
Aug 10, 2026 BUY Strong Buy
+61.5% avg upside
9 analysts
$35.00
50.51% Upside
-64.3% Β·
WGS
GeneDx Holdings
Aug 04, 2026 BUY Strong Buy
+22.6% avg upside
10 analysts
$90.00
30.38% Upside
-33.3% Β·
VCYT
Veracyte
Aug 03, 2026 HOLD Strong Buy
+4.5% avg upside
19 analysts
$50.00
0.06% Downside
-46.0% Β·
GH
Guardant Health
Aug 02, 2026 BUY Strong Buy
-3.1% avg upside
33 analysts
$205.00
14.58% Upside
-9.8% Β·
CSTL
Castle Biosciences
Aug 02, 2026 BUY Strong Buy
+16.9% avg upside
10 analysts
$40.00
7.59% Upside
+8.4% Β·
GB:ONT
Oxford Nanopore Technologies PLC
Jul 14, 2026 BUY Strong Buy
-0.1% avg upside
7 analysts
$180.00
19.06% Downside
+79.9% Β·
ONT
Onterris
Jun 18, 2026 BUY Buy
+241.0% avg upside
10 analysts
$267.94
1695.93% Upside
+36.5% Β·
QSI
Quantum-Si
May 08, 2026 HOLD Buy
+57.6% avg upside
3 analysts
$1.00
31.46% Downside
+16.9% Β·
TTOO
T2 Biosystems
Jul 29, 2024 HOLD Buy
+1015078.6% avg upside
10 analysts
$5.00
714185.66% Upside
Β· Β·
BWAY
Brainsway
Jun 01, 2021 BUY Strong Buy
+25.4% avg upside
10 analysts
$15.00
32.05% Upside
-84.2% Β·
PAVM
PAVmed
Mar 29, 2021 BUY Strong Buy
+2002.6% avg upside
5 analysts
$8.00
310.29% Upside
Β· Β·
VNRX
VolitionRX
Mar 09, 2021 BUY Strong Buy
+4956.3% avg upside
11 analysts
$8.00
3996.23% Upside
Β· Β·
AWHL
Aspira Women's Health
Jan 28, 2021 BUY Strong Buy
+2471.4% avg upside
6 analysts
$10.00
4661.90% Upside
Β· Β·
πŸ”’ 23 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Kyle Mikson CFA β€” Frequently Asked Questions
How accurate are Kyle Mikson CFA's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Kyle's ratings were profitable over a one-year hold, with an average return of +7.9% per rating, or +7.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kyle ranked on 13Foresight?
Kyle Mikson CFA is currently ranked #184 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kyle cover?
Kyle most recently has ratings on ILMN, CDNA, RGEN, LUCD, NTRA, CAI, XGN, TWST, TEM, TXG, GRAL, PACB and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.